Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEG35156 in Relapsed/Refractory CLL and Indolent B-Cell Lymphomas
NCT00768339Phase 2Terminated
- Sponsor
- Aegera Therapeutics
- Start
- Sep 2008
- Primary completion
- Jun 2011
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
A Phase 2 trial of AEG35156 in chronic lymphocytic leukemia (CLL), indolent B-cell lymphoma, sponsored by Aegera Therapeutics. Started Sep 2008; status: terminated.
02
Drugs
AEG35156
03
Conditions
chronic lymphocytic leukemia (CLL)indolent B-cell lymphoma
Beyond the preview
Go deeper on NCT00768339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00768339.